Additionally, we investigated whether prolonged low‐dose decitabine pretreatment could chemo‐sensitize MLL‐rearranged ALL cells toward chemotherapeutics currently used in the treatment of this type of leukemia, as well as toward various other epigenetic or anti‐neoplastic compounds. The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.